| Randomised Clinical Trials | Effect size (95%CI) | Reference |
|---|---|---|
| Vaginal Microbicide | ||
|
CAPRISA 004 - peri-coital tenofovir gel (Women in South Africa) |
39% (6; 60) | [81] |
|
MTN003/VOICE - daily tenofovir gel (Women in South Africa, Uganda, Zimbabwe) |
15% (-21; 40) | [82] |
|
FACTS 001- peri-coital tenofovir gel (Women in South Africa) |
0% (-40; 30) | [83] |
|
MTN-020-ASPIRE -monthly vaginal ring containing dapivirine (Women in Malawi, South Africa, Uganda, and Zimbabwe) |
27% (1; 46) | [89] |
|
IPM 027/Ring Study monthly vaginal ring containing dapivirine (Women in South Africa and Uganda) |
30.7% (0.90-51.5) | [90] |
| Oral Pre-exposure prophylaxis | ||
|
IPERGAY - on demand emtricitabine and tenofovir* (Men who have sex with men in France) |
86% (39; 99) | [88] |
|
PROUD - daily emtricitabine and tenofovir (Men who have sex with men in United Kingdom) |
86% (62; 96) | [87] |
|
Partners PrEP - daily emtricitabine and tenofovir (HIV serodiscordant couples in Kenya, Uganda) |
75% (55; 87) | [86] |
|
Partners PrEP - daily tenofovir (HIV serodiscordant couples in Kenya, Uganda) |
67% (44; 81) | [86] |
|
TDF2 - daily emtricitabine and tenofovir (Heterosexuals men and women in Botswana) |
62% (22; 84) | [85] |
|
iPrEx - daily emtricitabine and tenofovir (Men who have sex with men in America’s, Thailand, South Africa) |
44% (15; 63) | [94] |
|
FEMPrEP - daily emtricitabine and tenofovir (Women in Kenya, South Africa, Tanzania) |
6% (-52; 41) | [84] |
|
MTN003/VOICE - daily emtricitabine and tenofovir (Women in South Africa, Uganda, Zimbabwe) |
4% (-49; 27) | [82] |
|
MTN003/VOICE - daily tenofovir (Women in South Africa, Uganda, Zimbabwe) |
-49% (-129; 3) | [82] |
| Other | ||
|
HPTN 052- Antiretroviral therapy as prevention (HIV serodiscordant couples in Africa, Asia, America) |
96% (73; 99) | [8] |
|
Medical Male circumcision (Men in South Africa, Kenya, Uganda) |
61% (34; 77) 60% (32; 77) 51% (16; 72) |
[4-6] |
|
STD treatment (Men and women in Mwanza, Tanzania) |
42% (21; 58) | [95] |